Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.


Journal Article

We studied the pharmacokinetics and in vivo antifungal action of SCH39304, a new antifungal azole compound, in rabbits. It crossed the blood-cerebrospinal fluid barrier in the presence or absence of meningeal inflammation, reaching approximately 60% of the simultaneous concentrations in serum. In the treatment of experimental cryptococcal meningitis, SCH39304 was as effective as fluconazole in reducing yeast counts in the subarachnoid space. SCH39304 and fluconazole both were highly effective against candida endophthalmitis, sterilizing the vitreous humor and the choroid and retina. SCH39304 suppressed candida endocarditis and reduced yeast counts in the kidney at all doses tested. SCH39304 was effective in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. Further investigations in humans are warranted.

Full Text

Duke Authors

Cited Authors

  • Perfect, JR; Wright, KA; Hobbs, MM; Durack, DT

Published Date

  • October 1989

Published In

Volume / Issue

  • 33 / 10

Start / End Page

  • 1735 - 1740

PubMed ID

  • 2556078

Pubmed Central ID

  • 2556078

International Standard Serial Number (ISSN)

  • 0066-4804

Digital Object Identifier (DOI)

  • 10.1128/aac.33.10.1735


  • eng

Conference Location

  • United States